{"success":true,"data":{"pressRelease":{"id":"164799","rtpr_id":"nGNX9QhtzB-20261008","ticker":"QSI","exchange":"NASDAQ","all_tickers":["QSI"],"title":"Quantum-Si Demonstrates Detection of 19 Amino Acids in Proteus™ Development Program","author":"Globe Newswire","published_at":"2026-10-08T20:05:00.244Z","article_body":"BRANFORD, Conn., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated\n(Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics\ncompany redefining protein analysis through single-molecule protein\nsequencing, today announced that it has demonstrated detection of 19 amino\nacids in its Proteus™ development program and is now working to deploy that\ncapability into a developmental sequencing kit for routine use on integrated\nProteus instruments. Building on the interim Proteus results presented at the\n2026 World HUPO Congress, this latest milestone reflects continued progress in\nthe Company’s amino acid recognizer program and reinforces its confidence\nthat detection of all 20 amino acids is well within reach by year-end 2026.\n\n“Demonstrating detection of 19 amino acids is an important step toward our\ngoal of detecting all 20 amino acids by the end of 2026,” said Jeff Hawkins,\nPresident and Chief Executive Officer of Quantum-Si. “We are now focused on\ndeploying this capability into a developmental sequencing kit for use by our\nR&D team. Given the pace of progress in our recognizer program, we are growing\nincreasingly confident in our ability to demonstrate detection of all 20 amino\nacids by year-end 2026.”\n\nHawkins continued, “At World HUPO, we demonstrated that Proteus delivered\nsignificant improvements across every key measure of sequencing performance\nusing a developmental kit that detects 18 amino acids. Once this 19-amino-acid\ncapability is deployed into a developmental sequencing kit, we expect it to\neven further increase Proteus sequencing performance. Combined with the\nsignificant performance improvements presented at World HUPO, this progress\nfurther strengthens our confidence in the continued advancement of the Proteus\nplatform toward commercial launch in the second quarter of 2027.”\n\nAbout Quantum-Si Incorporated\nQuantum-Si is transforming proteomics with a benchtop platform that brings\nsingle-molecule protein analysis to every lab, everywhere. The Company’s\nplatform enables real-time, kinetic-based detection and allows researchers to\nmove beyond traditional, multistep workflows and directly access dynamic,\nfunctional protein insights with unparalleled resolution. By making protein\nanalysis simpler, faster, and more informative, Quantum-Si is accelerating\nproteomic discoveries to improve the way we live. Learn more at quantum-si.com\n(https://www.globenewswire.com/Tracker?data=2asfH09JtDzx3JmpNeYnRiGHmZUVdQwMmdGwR-l_Eiqpxqg6BkyH6YS_af8CCZfrllyKjKeGV3aeRoyzpa7--PMIPQa5KWCITawbOLXcVdXRCvHpTQsxFJD7j4hpkjnYnThG86kwlkXLqW3n1pYk--xSFIsnLUrl2A9P7u7q1xG8PHqsY9zPqutEnUptyOnCMBNiLTkfO76RA4XWOXOT6DAaOAQtR7TVdqGgwxnyLiJlgHYmyfxkcPnENm3BRV8yOzIyD7tbQFEQvaiPbrDQsB2li6YMkmzS4wmhMe9FvQF432mnwkmcRszquC6Ya9aAbwiG3IuPRw2tDSO_38HH-w==)\nor follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=Bn4xJ1gokXTjllcIp6ySJlML9cDRtJtKGb9iIrKFrtqi8LrN9hamkxkkwwyFEPBIniu43L_yHPaP5lo7vVN0FOiuyPMDY9TZmn3GEJk5Wr9vz3sGV8nPjnX40tfYWzVUSvzRTtr8Qzvc4wvwFsLQR0eYB5Ig09O6W9HqGis-vNSks2bAeUnrV2Zxd69JcClfs-_4s5tToZxwjv6Jt8Ps_TrPhlUrmIcAIO4K-D94MZZ4lvVwm4r_lDXqLEEa_lVgS3pRrbdhPWUe2FyKXS4EJN4zBvqZEkYuoCcprQla5NBKCe14OpRaO0V7bfGrDpNKzCn76crfg1MFJehqE4J3uQ==)\nor X\n(https://www.globenewswire.com/Tracker?data=9lKwrgWq150aiazqVAYGbvjQbrAiGj3OU6bgPeMgDs0VtFzjHuKNWXS58goX2ao_YJ3aqe5I4s3lDNg9QUSHOqLDTnDo08dmgJ4DfIe8NUpRP8I-q7A6YK8lucD0iRV5CdToQSdXcuC5wGzYQzlRz1K6ncdh01UeG6g7XKMtZqOMV0vo2P5NM6Woq9fIWxm6Ac_dLzdzz_19tDTEE-RWalCIZxEFswK6Tt-pBHpFb-LZgTXD5xJ228fXuoDE1tFJPlJX5ZB2CDl8a_JQvGSIR-dz-v9Blza-lYqH0MT8R18=).\n\nForward-Looking Statements\nThis press release includes “forward-looking statements” within the\nmeaning of the “safe harbor” provisions of the United States Private\nSecurities Litigation Reform Act of 1995. The actual results of the Company\nmay differ from its expectations, estimates, and projections and,\nconsequently, you should not rely on these forward-looking statements as\npredictions of future events. Words such as “expect,” “estimate,”\n“project,” “budget,” “forecast,” “anticipate,” “intend,”\n“plan,” “may,” “will,” “could,” “should,” “believes,”\n“predicts,” “potential,” “continue,” and similar expressions (or\nthe negative versions of such words or expressions) are intended to identify\nsuch forward-looking statements. These forward-looking statements include,\nwithout limitation, the Company’s expectations with respect to future\nperformance and development and commercialization of products, services and\napplications, its anticipated cash runway, the anticipated timing of product\nlaunches and product capabilities, including the expected demonstration of\ndetection of all 20 amino acids by year-end 2026 and the expected amino acid\ndetection capabilities of Proteus at launch, the Company’s current belief\nregarding remaining technical challenges associated with Proteus\ncommercialization, the expected timing and successful completion of deployment\ninto a developmental sequencing kit, system integration, optimization,\nverification, validation and launch-readiness activities, the expected\nbenefits of the Company’s development-process, organizational and\ncost-control actions, including the reduction in force, and any financial\nguidance.\n\nThese forward-looking statements involve significant risks and uncertainties\nthat could cause the actual results to differ materially from those discussed\nin the forward-looking statements. Many of these factors are outside the\nCompany’s control and are difficult to predict. Factors that may cause such\ndifferences include, but are not limited to: the inability to maintain the\nlisting of the Company’s Class A common stock on The Nasdaq Stock Market;\nthe ability of the Company to grow and manage growth and retain its key\nemployees; the Company’s ongoing leadership transitions and succession\nplanning; the Company’s ability to successfully implement organizational\nchanges, including workforce reductions, cost-control actions and\ndevelopment-process improvements, without disrupting product development,\nlaunch readiness, employee retention or customer engagement; the possibility\nthat additional technical, integration, performance, reliability,\nverification, validation or launch-readiness challenges may arise or take\nlonger or cost more to address than expected; changes in applicable laws or\nregulations; the ability of the Company to raise financing in the future; the\nsuccess, cost and timing of the Company’s product development and\ncommercialization activities, including the use and benefit of artificial\nintelligence in these and other activities; the commercialization and adoption\nof the Company’s existing products and the success of any product the\nCompany may offer in the future, including Proteus; the potential attributes\nand benefits of the Company’s commercialized Platinum protein sequencing\ninstruments and kits and the Company’s other products (including Proteus)\nonce commercialized; the Company’s ability to obtain and maintain regulatory\napproval for its products, and any related restrictions and limitations of any\napproved product; the Company’s ability to identify, in-license or acquire\nadditional technology; the Company’s ability to maintain its existing lease,\nlicense, manufacture and supply agreements; the Company’s ability to compete\nwith other companies currently marketing or engaged in the development or\ncommercialization of products and services that serve customers engaged in\nproteomic analysis, many of which have greater financial and marketing\nresources than the Company; the size and growth potential of the markets for\nthe Company’s products and services, and its ability to serve those markets\nonce commercialized, either alone or in partnership with others; the\nCompany’s estimates regarding future expenses, future revenue, capital\nrequirements and needs for additional financing; the Company’s financial\nperformance; the Company’s defense and initiation of litigation matters; and\nother risks and uncertainties described under “Risk Factors” in the\nCompany’s most recent Annual Report on Form 10-K and Quarterly Reports on\nForm 10-Q and in the Company’s other filings with the SEC. The Company\ncautions that the foregoing list of factors is not exclusive. The Company\ncautions readers not to place undue reliance upon any forward-looking\nstatements, which speak only as of the date made. The Company does not\nundertake or accept any obligation or undertaking to release publicly any\nupdates or revisions to any forward-looking statements to reflect any change\nin its expectations or any change in events, conditions, or circumstances on\nwhich any such statement is based.\n\nInvestor and Media Contact\nJeff Keyes\nChief Financial Officer\nir@quantum-si.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/e6ddb33e-9b4c-4243-933e-2f929433ee3a)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX9QhtzB-20261008","title":"Quantum-Si Demonstrates Detection of 19 Amino Acids in Proteus™ Development Program","author":"Globe Newswire","ticker":"QSI","created":"2026-10-08T20:05:00.244Z","tickers":["QSI"],"exchange":"NASDAQ","article_body":"BRANFORD, Conn., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated\n(Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics\ncompany redefining protein analysis through single-molecule protein\nsequencing, today announced that it has demonstrated detection of 19 amino\nacids in its Proteus™ development program and is now working to deploy that\ncapability into a developmental sequencing kit for routine use on integrated\nProteus instruments. Building on the interim Proteus results presented at the\n2026 World HUPO Congress, this latest milestone reflects continued progress in\nthe Company’s amino acid recognizer program and reinforces its confidence\nthat detection of all 20 amino acids is well within reach by year-end 2026.\n\n“Demonstrating detection of 19 amino acids is an important step toward our\ngoal of detecting all 20 amino acids by the end of 2026,” said Jeff Hawkins,\nPresident and Chief Executive Officer of Quantum-Si. “We are now focused on\ndeploying this capability into a developmental sequencing kit for use by our\nR&D team. Given the pace of progress in our recognizer program, we are growing\nincreasingly confident in our ability to demonstrate detection of all 20 amino\nacids by year-end 2026.”\n\nHawkins continued, “At World HUPO, we demonstrated that Proteus delivered\nsignificant improvements across every key measure of sequencing performance\nusing a developmental kit that detects 18 amino acids. Once this 19-amino-acid\ncapability is deployed into a developmental sequencing kit, we expect it to\neven further increase Proteus sequencing performance. Combined with the\nsignificant performance improvements presented at World HUPO, this progress\nfurther strengthens our confidence in the continued advancement of the Proteus\nplatform toward commercial launch in the second quarter of 2027.”\n\nAbout Quantum-Si Incorporated\nQuantum-Si is transforming proteomics with a benchtop platform that brings\nsingle-molecule protein analysis to every lab, everywhere. The Company’s\nplatform enables real-time, kinetic-based detection and allows researchers to\nmove beyond traditional, multistep workflows and directly access dynamic,\nfunctional protein insights with unparalleled resolution. By making protein\nanalysis simpler, faster, and more informative, Quantum-Si is accelerating\nproteomic discoveries to improve the way we live. Learn more at quantum-si.com\n(https://www.globenewswire.com/Tracker?data=2asfH09JtDzx3JmpNeYnRiGHmZUVdQwMmdGwR-l_Eiqpxqg6BkyH6YS_af8CCZfrllyKjKeGV3aeRoyzpa7--PMIPQa5KWCITawbOLXcVdXRCvHpTQsxFJD7j4hpkjnYnThG86kwlkXLqW3n1pYk--xSFIsnLUrl2A9P7u7q1xG8PHqsY9zPqutEnUptyOnCMBNiLTkfO76RA4XWOXOT6DAaOAQtR7TVdqGgwxnyLiJlgHYmyfxkcPnENm3BRV8yOzIyD7tbQFEQvaiPbrDQsB2li6YMkmzS4wmhMe9FvQF432mnwkmcRszquC6Ya9aAbwiG3IuPRw2tDSO_38HH-w==)\nor follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=Bn4xJ1gokXTjllcIp6ySJlML9cDRtJtKGb9iIrKFrtqi8LrN9hamkxkkwwyFEPBIniu43L_yHPaP5lo7vVN0FOiuyPMDY9TZmn3GEJk5Wr9vz3sGV8nPjnX40tfYWzVUSvzRTtr8Qzvc4wvwFsLQR0eYB5Ig09O6W9HqGis-vNSks2bAeUnrV2Zxd69JcClfs-_4s5tToZxwjv6Jt8Ps_TrPhlUrmIcAIO4K-D94MZZ4lvVwm4r_lDXqLEEa_lVgS3pRrbdhPWUe2FyKXS4EJN4zBvqZEkYuoCcprQla5NBKCe14OpRaO0V7bfGrDpNKzCn76crfg1MFJehqE4J3uQ==)\nor X\n(https://www.globenewswire.com/Tracker?data=9lKwrgWq150aiazqVAYGbvjQbrAiGj3OU6bgPeMgDs0VtFzjHuKNWXS58goX2ao_YJ3aqe5I4s3lDNg9QUSHOqLDTnDo08dmgJ4DfIe8NUpRP8I-q7A6YK8lucD0iRV5CdToQSdXcuC5wGzYQzlRz1K6ncdh01UeG6g7XKMtZqOMV0vo2P5NM6Woq9fIWxm6Ac_dLzdzz_19tDTEE-RWalCIZxEFswK6Tt-pBHpFb-LZgTXD5xJ228fXuoDE1tFJPlJX5ZB2CDl8a_JQvGSIR-dz-v9Blza-lYqH0MT8R18=).\n\nForward-Looking Statements\nThis press release includes “forward-looking statements” within the\nmeaning of the “safe harbor” provisions of the United States Private\nSecurities Litigation Reform Act of 1995. The actual results of the Company\nmay differ from its expectations, estimates, and projections and,\nconsequently, you should not rely on these forward-looking statements as\npredictions of future events. Words such as “expect,” “estimate,”\n“project,” “budget,” “forecast,” “anticipate,” “intend,”\n“plan,” “may,” “will,” “could,” “should,” “believes,”\n“predicts,” “potential,” “continue,” and similar expressions (or\nthe negative versions of such words or expressions) are intended to identify\nsuch forward-looking statements. These forward-looking statements include,\nwithout limitation, the Company’s expectations with respect to future\nperformance and development and commercialization of products, services and\napplications, its anticipated cash runway, the anticipated timing of product\nlaunches and product capabilities, including the expected demonstration of\ndetection of all 20 amino acids by year-end 2026 and the expected amino acid\ndetection capabilities of Proteus at launch, the Company’s current belief\nregarding remaining technical challenges associated with Proteus\ncommercialization, the expected timing and successful completion of deployment\ninto a developmental sequencing kit, system integration, optimization,\nverification, validation and launch-readiness activities, the expected\nbenefits of the Company’s development-process, organizational and\ncost-control actions, including the reduction in force, and any financial\nguidance.\n\nThese forward-looking statements involve significant risks and uncertainties\nthat could cause the actual results to differ materially from those discussed\nin the forward-looking statements. Many of these factors are outside the\nCompany’s control and are difficult to predict. Factors that may cause such\ndifferences include, but are not limited to: the inability to maintain the\nlisting of the Company’s Class A common stock on The Nasdaq Stock Market;\nthe ability of the Company to grow and manage growth and retain its key\nemployees; the Company’s ongoing leadership transitions and succession\nplanning; the Company’s ability to successfully implement organizational\nchanges, including workforce reductions, cost-control actions and\ndevelopment-process improvements, without disrupting product development,\nlaunch readiness, employee retention or customer engagement; the possibility\nthat additional technical, integration, performance, reliability,\nverification, validation or launch-readiness challenges may arise or take\nlonger or cost more to address than expected; changes in applicable laws or\nregulations; the ability of the Company to raise financing in the future; the\nsuccess, cost and timing of the Company’s product development and\ncommercialization activities, including the use and benefit of artificial\nintelligence in these and other activities; the commercialization and adoption\nof the Company’s existing products and the success of any product the\nCompany may offer in the future, including Proteus; the potential attributes\nand benefits of the Company’s commercialized Platinum protein sequencing\ninstruments and kits and the Company’s other products (including Proteus)\nonce commercialized; the Company’s ability to obtain and maintain regulatory\napproval for its products, and any related restrictions and limitations of any\napproved product; the Company’s ability to identify, in-license or acquire\nadditional technology; the Company’s ability to maintain its existing lease,\nlicense, manufacture and supply agreements; the Company’s ability to compete\nwith other companies currently marketing or engaged in the development or\ncommercialization of products and services that serve customers engaged in\nproteomic analysis, many of which have greater financial and marketing\nresources than the Company; the size and growth potential of the markets for\nthe Company’s products and services, and its ability to serve those markets\nonce commercialized, either alone or in partnership with others; the\nCompany’s estimates regarding future expenses, future revenue, capital\nrequirements and needs for additional financing; the Company’s financial\nperformance; the Company’s defense and initiation of litigation matters; and\nother risks and uncertainties described under “Risk Factors” in the\nCompany’s most recent Annual Report on Form 10-K and Quarterly Reports on\nForm 10-Q and in the Company’s other filings with the SEC. The Company\ncautions that the foregoing list of factors is not exclusive. The Company\ncautions readers not to place undue reliance upon any forward-looking\nstatements, which speak only as of the date made. The Company does not\nundertake or accept any obligation or undertaking to release publicly any\nupdates or revisions to any forward-looking statements to reflect any change\nin its expectations or any change in events, conditions, or circumstances on\nwhich any such statement is based.\n\nInvestor and Media Contact\nJeff Keyes\nChief Financial Officer\nir@quantum-si.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/e6ddb33e-9b4c-4243-933e-2f929433ee3a)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-08T20:05:00.283871856Z","server_sent_at_ms":1791489900283},"received_at":"2026-10-08T20:05:00.439Z","source_url":null},"analysis":{"id":"153209","press_release_id":"164799","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Pre-commercial company; milestone still falls short of full 20-amino-acid capability","Forward-looking statements reference workforce reductions, leadership transitions, and Nasdaq listing-maintenance risk"],"eventType":"operations_update","narrative":"Quantum-Si demonstrated detection of 19 amino acids in its Proteus development program, up from 18 shown at the 2026 World HUPO Congress.\n\nThe company is now deploying the capability into a developmental sequencing kit and targets detection of all 20 amino acids by year-end 2026.\n\nManagement reiterated confidence in Proteus commercial launch in the second quarter of 2027, though forward-looking statements flag remaining technical, integration, and launch-readiness risks.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Proteus one amino acid from full-panel detection ahead of year-end goal -- watch for the 20/20 milestone as a de-risking catalyst before Q2 2027 launch."},"keyFigures":{"customDimensions":{"target_amino_acids":20,"amino_acids_detected":19,"target_full_detection":"year-end 2026","proteus_commercial_launch":"Q2 2027"}},"quotedText":"Demonstrating detection of 19 amino acids is an important step toward our goal of detecting all 20 amino acids by the end of 2026","namedEntities":{"people":[{"name":"Jeff Hawkins","role":"President and CEO"},{"name":"Jeff Keyes","role":"CFO"}],"products":["Proteus","Platinum"],"companies":[{"name":"Quantum-Si Incorporated","ticker":"QSI"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Incremental R&D milestone (19 of 20 amino acids detected) on a pre-commercial development platform. Positive progress signal but not revenue-moving or a binary event; commercial launch remains targeted for Q2 2027."},"tickerRelevance":{"others":[],"primary":"QSI"},"globalImportance":18,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"incremental R&D milestone","preCommercial":true,"issuerAuthored":true}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Quantum-Si demonstrated detection of 19 amino acids in its Proteus development program, up from 18 shown at the 2026 World HUPO Congress.\n\nThe company is now deploying the capability into a developmental sequencing kit and targets detection of all 20 amino acids by year-end 2026.\n\nManagement reiterated confidence in Proteus commercial launch in the second quarter of 2027, though forward-looking statements flag remaining technical, integration, and launch-readiness risks.","key_figures":{"customDimensions":{"target_amino_acids":20,"amino_acids_detected":19,"target_full_detection":"year-end 2026","proteus_commercial_launch":"Q2 2027"}},"named_entities":{"people":[{"name":"Jeff Hawkins","role":"President and CEO"},{"name":"Jeff Keyes","role":"CFO"}],"products":["Proteus","Platinum"],"companies":[{"name":"Quantum-Si Incorporated","ticker":"QSI"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-08T20:05:09.842Z","global_importance":18,"audience_relevance":20,"importance_components":{"tickerTier":"small-cap","eventGravity":"incremental R&D milestone","preCommercial":true,"issuerAuthored":true}},"durationMs":9325,"modelName":"glm-5.3-flashx"}}